Condition: Chronic Idiopathic Constipation (CIC) · Sponsor: Ardelyx
This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.
This description comes directly from the study's public registry record.
Marica Tambongco · (617) 875-7968 · mtambongco@ardelyx.com
Always discuss trial participation with your own doctor first.
| G & L Research, LLC | Foley, Alabama, United States | Recruiting |
| The Center for Clinical Trials | Saraland, Alabama, United States | Recruiting |
| Arizona Liver Health - Chandler | Chandler, Arizona, United States | Recruiting |
| Elite Clinical Studies | Phoenix, Arizona, United States | Recruiting |
| Clinical Research Institute of Arizona, LLC | Sun City West, Arizona, United States | Recruiting |
| Del Sol Research Management, LLC | Tucson, Arizona, United States | Recruiting |
| Arkansas Gastroenterology - North Little Rock | North Little Rock, Arkansas, United States | Recruiting |
| Hope Clinical Research - Canoga Park | Canoga Park, California, United States | Recruiting |
| GW Research Inc. | Chula Vista, California, United States | Recruiting |
| Erick H. Alayo Medical Corporation | Chula Vista, California, United States | Recruiting |
| 310 Clinical Research | Inglewood, California, United States | Recruiting |
| Om Research LLC | Lancaster, California, United States | Recruiting |
+ 97 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07382167